Draft ASHP Guidelines on Pharmacists Relationships with Industry
|
|
- Marjory Watkins
- 5 years ago
- Views:
Transcription
1 Draft ASHP Guidelines on Pharmacists Relationships with Industry Pharmacists can choose to pursue an ethic that reciprocates trust with trustworthy behavior. Pharmacists stand to benefit individually and professionally by having a widely accepted, intrinsic set of ethical standards reflecting fidelity to patients, rather than having ethical behavior that is imposed by regulatory authorities in the wake of scandals attracting negative media attention. David Banks 1 Pharmacists, like other healthcare providers, have a paradoxical relationship with drug and device manufacturers. 1 Drug products and delivery devices are essential to the care that pharmacists provide to patients. Drug manufacturers and other healthcare businesses (e.g., information technology and automation companies) create innovative treatments, promote the development and dissemination of information about the safe and effective use of their products of a safer and more effective medication-use process, and often provide valuable information for pharmacists and free or low-cost treatment for patients. Although the interests of these businesses often coincide with those of patients, healthcare practitioners recognize that these organizations are for-profit entities whose overriding interest in maximizing sales may lead to tragic results. 2 There has been a continuing growth of interest in addressing the potential for conflicts of interest in the practice of healthcare. 3 In 2002, the Pharmaceutical Research and Manufacturers of America (PhRMA) published its first Code on Interactions with Healthcare Professionals 4 ; that document was updated in 2008 and took effect in January The Department of Health and Human Services Office of the Inspector General (OIG) issued its Compliance Program Guidance for Pharmaceutical Manufacturers in In 2004, the Accreditation Council for Continuing Medical Education (ACCME) published guidance related to commercial support of continuing education, and in 2014 the Accreditation Council for Pharmacy Education (ACPE) updated its guidance on the topic, adapted from the ACCME standards. 7,8 The American College of Clinical Pharmacy (ACCP) updated its guidelines on ethical interactions with industry in The Physician Payments Sunshine Act of 2009 mandated that manufacturers report all financial support given to physicians or hospitals that accept federal reimbursement through Medicare and Medicaid in order to address conflicts of interest. 10 Within the same year, the Institute of Medicine (IOM) published its report, Conflict of Interest in Medical Research, Education, and Practice. 11 These reports characterized pharmacists as an adjacent profession that should follow the physician model managing conflicts of interest. The IOM also recommended that policies and procedures address accountability in the instance that a This draft document is intended for review purposes only. It is not official ASHP policy. This document may not be reproduced, circulated, or quoted (except for review purposes) without prior written permission from ASHP.
2 Draft ASHP Guidelines on Pharmacists Relationships with Industry breach is made. A parallel organization, the Advanced Medical Technology Association, published guidelines for interactions with healthcare professionals in the same year. 12 Pharmacists practices should be guided by what is best for patients. 13 Their judgment and the appearance of their objectivity should not be influenced by gifts or other benefits from commercial interests. ASHP recognizes that relationships between pharmacists and commercial interest are inevitable. Keeping these relationships ethical will prove beneficial to patients, pharmacists, and industry. Pharmacists have a professional obligation to be vigilant regarding any potential relationship that could result in a real or perceived conflict of interest. They must also consider how such an association could undermine their relationships with patients and colleagues or tarnish the reputation of pharmacy as a profession. The purpose of these guidelines is to outline policies and procedures that should guide pharmacists relationships with industry. These guidelines apply to any interaction between a healthcare-related proprietary entity and a pharmacist that might cause or appear to cause a conflict of interest. The guidelines address gifts, hospitality, and travel; educational programs; consultancy and research arrangements; disclosure; and activities of vendors representatives. ASHP has attempted to make these guidelines consistent with other organizations guidance on relations with industry. Where there are differences, or where guidance is lacking, pharmacists should apply their professional judgment. Defining Conflict of Interest Definitions of conflict of interest vary, but there is general agreement that a conflict of interest contains two elements: the presence of interests other than those dictated by professional responsibility and the opportunity to take actions that would further those interests. A conflict of interest arises when a person has a private or personal interest sufficient to appear to influence the objective exercise of his or her official duties. 14 A private interest is an interest based on a relationship with another person or organization, 1 such as an interest in the success of a friend, a non-spouse family member, or an organization. A personal interest is a self-interest and may involve financial or other personal incentives (e.g., recognition or advancement). A conflict of interest arises when these interests affect or appear to affect actions taken on behalf of the person whose interest the professional is entrusted with (in the case of pharmacists, the patient). For example, ACPE considers financial relationships to create actual conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CPE [continuing professional education] about the products or services of that commercial interest. 7 Because it is only human nature to overestimate one s ability to identify and address potential conflicts of interest, hospitals and health systems must develop and enforce policies and procedures regarding employee conflicts of interest. Pharmacists should take a leadership
3 Draft ASHP Guidelines on Pharmacists Relationships with Industry role in developing and enforcing those policies and procedures for pharmacy staff, recognizing that different responsibilities will require different approaches to conflict of interest management and resolution. In all cases, however, pharmacists should recognize that even the appearance of a conflict of interest is sufficient to warrant a deterrent policy and that mere disclosure of a conflict of interest does not resolve the conflict. Gifts, Hospitality, and Subsidies Gifts, hospitality, or subsidies offered to pharmacists by industry (whether offered directly by a vendor, through intermediaries, or from a company) should not be accepted. Acceptance might influence or appear to influence the objectivity of clinical judgment or drug product selection and procurement. Additionally, PhRMA code prohibits the distribution of gifts that might induce conflict of interest, such as entertainment or recreation items. 5 Public opinion of healthcare professionals dedication to patient welfare above all else may be undermined if that care is perceived to be influenced by industry gifts. 13 It is human nature for the recipient of a gift from a company sales representative to associate feelings about the gift or the representative with feelings about the company s product. Research has also shown a positive correlation between gift value and level of influence from industry. 15 Pharmacists have a responsibility to resolve even the appearance of conflicts of interest regarding their care for patients. Pharmacists should ensure that they are knowledgeable about relevant research on the risks and benefits of pharmaceutical and other products, and they should base their choices on this knowledge. 16 Personal or institutional gifts with conditions attached, such as gifts for top purchasers of a company s product, are not acceptable. 14 This prohibition includes personal discounts, educational grants, and contracts for research on a manufacturer s products. Detailed guidance for the pharmaceutical industry on appropriate interactions with healthcare professionals 5 and on preventing fraud and abuse in federal healthcare programs 6 has been published. Federal guidance to manufacturers suggests that they consider whether their practices or arrangements have the potential to increase costs to federal healthcare programs or their beneficiaries or could be construed as disguised discounts designed to circumvent the Medicaid Rebate Program Best Price calculation. 6 Pharmacists, as formulary decision-makers and purchasers, are in a position to generate federal healthcare business for manufacturers. Pharmacists should be aware that the federal anti-kickback statute makes it illegal for companies to offer anything of value in return for purchasing, leasing, ordering, or arranging for or recommending the purchase, lease, or ordering of any item or service reimbursable in whole or in part by a federal healthcare program. 6 Purchasers should be aware of their obligations in reporting discounts and submitting claims to federal programs.
4 Draft ASHP Guidelines on Pharmacists Relationships with Industry Hospital and health-system policies should prohibit gifts to pharmacists, although some institutions may make exception for small gifts that advance education about disease or treatment. If the organization's policy permits such education-related gifts, those gifts should not be of substantial value (less than $100), and the same policies should apply whether the gifts are offered directly by a vendor, through intermediaries, or from the company. PhRMA no longer considers it appropriate for items such as pens, notepads, and calendars to be distributed to healthcare professionals. 5 PhRMA guidelines stipulate that informational presentations should be limited to inoffice or in-hospital settings. 5 Pharmacists should not attend such events elsewhere, except as described in these guidelines. Although PhRMA guidelines permit company representatives to provide healthcare professionals and their staff with occasional, modest meals during these educational presentations, ASHP believes industry representatives should be prohibited from providing food in the workplace. If allowed, such food should be of nominal value and accepted only on an occasional basis. 12 Mechanisms must be in place to ensure that the educational purpose of such events is fulfilled 5 and that interactions between vendors and healthcare professionals and staff are appropriate. Continuing Education Guidance on subsidies for educational activities applies regardless of the setting in which, or the medium through which, the educational activity is offered. 16 ACPE no longer accredits pharmaceutical and biomedical device manufacturers as providers of continuing education (CE). 8 Educational grants from industry to CE providers to underwrite the costs of conferences, professional meetings, or staff development programs may contribute to the improvement of patient care and are permissible in certain cases. CE providers that accept industry funding for programs must develop and enforce strict policies for maintaining complete control of the program and its content. This includes identification of CE needs, determination of educational objectives, selection and presentation of content, selection of materials, selection of speakers, selection of venue, selection of all persons and organizations that will be in a position to influence the content of the CE (e.g., reviewers, planners, faculty), selection of educational methods, and evaluation of the activity. 5,7 The CE provider should require all persons contributing to the content of an educational activity to disclose all relevant financial and other relationships with commercial interests. The CE content, format of the activity and its related materials must promote improvements or quality in healthcare rather than promoting a commercial product or interest. 7 Presentations must give a fair, balanced, and unbiased view of potential options based on the evidence. Educational presentations from industry should not be product-specific; the use of generic names is required. 7 It is appropriate for faculty at conferences or meetings to accept reasonable honoraria and reimbursement for reasonable travel, lodging, and meal expenses directly from the CE
5 Draft ASHP Guidelines on Pharmacists Relationships with Industry provider. Accredited CE providers must have written policies and procedures governing honoraria and expense reimbursement for CE planners, faculty, and authors. Presentation of a poster does not in itself qualify a person as a faculty member for the purpose of these guidelines, but if ACPE-accredited CE is offered for the poster, all ACPE standards apply. Commercial support must take the form of educational grants to providers, and payment to practitioners should come directly from the provider or from the provider s joint sponsors or educational partners. 7 Pharmacists, pharmacy students, residents, and fellows attending a conference or program should not accept, directly or indirectly, industry payments to defray the costs of attending the conference. Contributions from industry to special or educational funds for pharmacy staff development are permissible as long as decisions regarding expenses from these funds are made by the healthcare institution and approved by the department of pharmacy. Approval by the next-higher management tier is also recommended. Pharmacists attending conferences or meetings should not accept direct subsidies from industry to pay the costs of travel, lodging, or other personal expenses, nor should they accept subsidies to compensate for their time. Pharmacists attending CE activities should not accept industry subsidies regardless of whether the source is a company s sales division, educational division, or other section of the company. 16 Honoraria should not be accepted for visits to tour a company or learn about its products. 16 Except for modest meals or social events held as part of the CE activities, they are attending, pharmacists should not accept subsidies for hospitality. 16 The primary activity at CE conferences should be educational, and educational activities should account for a substantial majority of the total conference time. 16 Social events or meals at CE activities should not compete with or take precedence over the educational events. 7 Product Promotion Product-promotion material or product-specific advertisement of any type is prohibited in or during CE activities. 7 The juxtaposition of editorial and advertising material on the same products or subjects must be avoided. 7 Payments by companies to providers for commercial exhibits and advertisements are not considered commercial support for CE activities, but providers are expected to use sound practices with respect to these promotional activities, keeping them separate from CE. 7 Consultants and Advisory Arrangements Consultants who provide genuine services for industry may receive reasonable compensation and accept reimbursement for travel, lodging, and meal expenses related to providing those services. Token consulting or advisory arrangements cannot be used to justify compensating pharmacists for their time, travel, lodging, and other out-of-pocket expenses. A bona fide
6 Draft ASHP Guidelines on Pharmacists Relationships with Industry consulting arrangement would, for example, clearly identifies the need for the consultant s services and a written contract specifies the nature of the services to be provided and the basis for payment for these services. 5 The criteria for selecting consultants would be directly related to the identified purpose (i.e., the consultant must have the expertise or experience being sought), and consultants should be selected by persons with the appropriate expertise to determine whether an individual meets those criteria. 5 PhRMA code states that the number of professionals compensated for consulting roles is no more than necessary. 5 The venue and circumstances of meetings between industry representatives and consultants must be "conducive to the consulting service," and the primary focus of such meetings must be activities related to those services. 5 The PhRMA Code states that resorts are not appropriate venues for such meetings. 5 Participation in speaker programs is a form of consultancy and is the subject of specific provisions of the PhRMA Code. 5 Some organizations have concluded that, in general, payment of expenses for speaker training sessions is not appropriate. 16 Health systems should not permit pharmacists to participate in company-sponsored speaker programs. Pharmacists who serve as consultants or advisors to industry while serving on or advising committees that determine formularies or develop clinical practice guidelines have an obligation to disclose and resolve any potential conflicts of interest between those roles. 17 Clinical Research Pharmacists who participate in practice-based research on pharmaceuticals, devices, or other topics should conduct their activities in accord with basic precepts of accepted scientific methodology. Practice-based drug studies that are, in effect, promotional schemes to increase the use of a product or program are unacceptable. When a company convenes a group to recruit clinical investigators or convenes a group of investigators to discuss their results, pharmacist investigators may accept payment of reasonable travel expenses if these meetings serve a genuine research purpose. Compensation for time and travel expenses to participate in a focus group may be appropriate if the focus group serves a genuine and exclusive research purpose and is not used for promotional purposes. 16 (Here, research does not include marketing research.) In evaluating the propriety of such meetings, pharmacists should consider whether the meeting is to improve research knowledge or to adjust studies to meet a company s marketing agenda. Remuneration for participating in industry-sponsored clinical research and publishing should follow accepted ethical standards. An extensive discussion of these topics is available in the American College of Clinical Pharmacy s position paper on industry relations. 9 Pharmacists should never accept authorship for ghost-written publications.
7 Draft ASHP Guidelines on Pharmacists Relationships with Industry Disclosure To fully inform audiences or users, those in a position to influence CE content should disclose all potential conflicts of interest (e.g., industry-sponsored consultant, speaker, or research funding arrangements). The PhRMA code recommends continuing disclosure for at least two years beyond agreement completion. 5 CE providers are required by accrediting agencies such as ACCME and ACPE to disclose to learners the source of all support from commercial interests. Providers should be able to show that all persons in a position to influence the content have disclosed to the provider all relevant financial relationships with any commercial interests. A mechanism must be in place for identifying and resolving all conflicts of interest in advance of the activity, including the possibility of disqualifying a potential speaker. Mere disclosure does not resolve a conflict of interest. Pharmacists involved in making formulary and medication-use decisions (e.g., members of and presenters to the pharmacy and therapeutics committee) have special obligations regarding conflicts of interest that are detailed in the ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System. 17 In addition, to provide an exemplary environment for learning and model appropriate behaviors, pharmacy residency preceptors and college of pharmacy faculty have an obligation to disclose potential conflicts of interests to their residents and students. Activities of Vendors Representatives ASHP recommends that health-system pharmacies develop specific policies and procedures for the activities of vendors representatives in their facilities. Policies should ensure that pharmacists practice and decision-making are in the best interests of patients and are not inappropriately influenced by industry representatives, as well as to make the best use of healthcare providers time and protect patients privacy. Vendors representatives are defined, for purposes of this document, as agents who promote products and provide information and services to healthcare providers on behalf of manufacturers and suppliers. These guidelines pertain to the activities of vendors who serve and interact with personnel in organized healthcare systems with respect to drug products; drug-related devices; and other equipment, supplies, and services purchased by pharmacies. Each health-system setting should develop its own specific policies and procedures relating to the activities of vendors representatives. The ASHP Guidelines for Selecting Pharmaceutical Manufacturers and Suppliers 18 and setting-specific conflict-of-interest policies may be helpful in the development of vendor relations policies and procedures. The policies and procedures should be developed by the setting s pharmacy and therapeutics committee (or equivalent body) and approved by higher authorities in the setting as required. Depending on the setting, policies and procedures may include the following:
8 Draft ASHP Guidelines on Pharmacists Relationships with Industry A defined scope of applicability. The vendors representatives to which any policies and procedures apply should be defined by the individual setting. For example, if the policies and procedures are applicable only to drug-product vendors representatives and not to those promoting medical surgical supplies, packaging equipment, or drug administration devices, this should be clearly stated. 2. Orientation of representatives. In some individual settings, vendors representatives receive an orientation packet upon their initial visit to the setting. Such a packet should contain a copy of the setting s policies and procedures concerning vendors. 3. Directory. In some settings, a file of current vendor contact information is maintained in the pharmacy or other designated department. A form or system for recording such information might include the following: The vendor s name, address, and and website addresses; The name, address, telephone numbers, answering service number (if any), e- mail address, and drug-product assignment (purview) of each representative; The name, address, telephone number, and address of the representative s manager; The names, telephone numbers, addresses, and emergency telephone numbers of the vendor s directors of distribution, sales, and product information (titles may vary); and The names, telephone numbers, and addresses of the vendor s medical director and research director (titles may vary). 4. Availability of vendor-contact information to professionals in the setting. In some settings, the pharmacy department is permitted to provide professional staff with the information in item 3 upon request. 5. Registration while on premises. Vendors representatives should be required to register with the pharmacy department, other designated department or system upon each visit. At such time, the vendors representatives should document the time and location of their appointments. A dated name badge should be prominently worn along with the representative s current vendor-supplied name tag (if any). 6. Permitted locations. All vendors should be restricted from patient care and pharmacy storage and work areas unless their presence is required for a specific need (e.g., demonstrating equipment). At such times the vendor should be accompanied and not allowed access to patient information or allowed to contact healthcare providers outside the specific identified need. 7. Appointments. Representatives should schedule appointments with appropriate healthcare providers. General access to healthcare facilities (i.e., without a specific appointment) should be prohibited.
9 Draft ASHP Guidelines on Pharmacists Relationships with Industry Exhibits. Vendors may be allowed to distribute educational material by arranging for organized, scheduled exhibits. Policies and procedures concerning the times, places, content, and conduct of such events should be established. At no time should these exhibits occur in patient care areas. 9. Dissemination of educational materials. Vendors should provide education only about products that are on the formulary. Direct marketing to students without the presence of a faculty professional should be prohibited. 10. Samples. Every organization should have and enforce policies and procedures with respect to product samples. The use of drug samples within the institution should be eliminated to the extent possible Noncompliance. Policies and procedures should exist to address noncompliance with the policies and procedures by either vendors representatives or professional staff. 12. Research. Each setting should have policies and procedures concerning research to be conducted on its premises. Pharmacists and vendors representatives should clearly differentiate research from sales and promotional activities, applying appropriate policies and procedures accordingly. 20 Manufacturers contracting procedures should clearly separate the awarding of research contracts from the marketing or promotion of their products. 6 Conclusion Relationships between pharmacists and commercial interests are inevitable. Keeping these relationships ethical will benefit patients, pharmacists, and industry. These guidelines outline policies and procedures that should guide pharmacists relationships with industry, but they cannot address every circumstance. Where guidance is lacking, pharmacists should apply their professional judgment regarding any action that might cause or appear to cause a conflict of interest. References 1. Banks D. Pharmacists, pharmaceutical manufacturers, and conflicts of interest. Am J Health-Syst Pharm. 2005; 62: Avorn J. Dangerous deception -- hiding the evidence of adverse drug effects. N Engl J Med. 2006; 355: Brennan TA, Rothman DJ, Blank L et al. Health industry practices that create conflicts of interest. JAMA. 2006; 295: PhRMA Code on Interactions with Healthcare Professionals. Washington, DC: Pharmaceutical Research and Manufacturers of America. Revised January PhRMA Code on Interactions with Healthcare Professionals. Washington, DC: Pharmaceutical Research and Manufacturers of America. Revised January Available at: (accessed 2017 Aug 1).
10 Draft ASHP Guidelines on Pharmacists Relationships with Industry Department of Health and Human Services Office of the Inspector General. OIG Compliance Program Guidance for Pharmaceutical Manufacturers. (accessed 2017 Aug 1). 7. Accreditation Council for Continuing Medical Education. Standards for Commercial Support: Standards to Ensure Independence in CME Activities (2004). (accessed 2017 Aug 1). 8. Accreditation Council for Pharmacy Education. ACPE Accreditation Standards for Continuing Pharmacy Education (CPE) Guidelines for Standards for Commercial Support- CPE Standard 5 (2014). for Standards for Commercial Support.pdf (accessed 2017 Aug 1). 9. American College of Clinical Pharmacy. Pharmacists and Industry: Guidelines for Ethical Interactions. Pharmacotherapy. 2008;28: Physician Payments Sunshine Act Affordable Care Act Section 6002 Final Rule. Available at: Final-Rule.pdf (accessed 2017 Aug 2017). 11. Institute of Medicine. Conflict of interest in medical research, education, and practice. Washington, DC: National Academies press: Advanced Medical Technology Association. Code of Ethics on Interactions with Healthcare Professionals. (accessed 1 Aug 2017). 13. Code of ethics for pharmacists. Available at: /media/assets/policy-guidelines/docs/endorsed-documents-code-of-ethics-forpharmacists.ashx (accessed 1 Aug 2017). 14. MacDonald M. Ethics and conflicts of interest. (accessed 1 Aug 2017). 15. Perry JE, Cox D, Cox AD. Trust and transparency: patient perceptions of physicians financial relationships with pharmaceutical companies. J Law Med Ethics Dec;42(4): Council on Ethical and Judicial Affairs of the American Medical Association. Guidelines on gifts to physicians from industry: an update. Food Drug Law J. 2001; 56: American Society of Health-System Pharmacists. ASHP guidelines on the pharmacy and therapeutics committee and the formulary system. Am J Health-Syst Pharm. 2008; 65: American Society of Hospital Pharmacists. ASHP Guidelines for Selecting Pharmaceutical Manufacturers and Suppliers. Am J Hosp Pharm. 1991; 48: American Society of Hospital Pharmacists. ASHP Guidelines: Minimum Standard for Pharmacies in Hospitals. Am J Health-Syst Pharm. 2013; 70: American Society of Hospital Pharmacists. ASHP Guidelines for Pharmaceutical Research in Organized Healthcare Settings. Am J Hosp Pharm. 1989; 46:
ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics. March 2018
ASSOCIATION FOR ACCESSIBLE MEDICINES Code of Business Ethics March 2018 Introduction Improving patient access to affordable medicines is a core value of companies that develop and manufacture generic and
More informationApproved by: UMMG Executive Committee. Date Approved: NOVEMBER 22, 2011
UMMG Policy Interactions with Health Industry Entities Approved by: UMMG Executive Committee Date Approved: NOVEMBER 22, 2011 Medical intellectual honesty, the application of best of scientific evidence,
More informationCode on Interactions with Healthcare. Professionals
Code on Interactions with Healthcare Professionals Table of Contents Preamble 1 Basis of Interactions 2 Informational Presentations by Pharmaceutical Company Representatives and Accompanying Meals 3 Prohibition
More informationDaiichi Sankyo Group Global Marketing Code of Conduct
Daiichi Sankyo Group Global Marketing Code of Conduct TABLE OF CONTENTS 1. PURPOSE... 3 2. SCOPE... 3 3. TERMS... 3 4. COMPLIANCE WITH LOCAL LAWS, REGULATIONS AND INDUSTRY CODES... 4 5. BASIS OF INTERACTIONS...
More informationVENDOR RELATIONS POLICY TRAINING
VENDOR RELATIONS POLICY TRAINING INTRODUCTION Vendor Relations Policy Key Points All employees of the University of California are subject to the conflict-of-interest provisions of the Political Reform
More informationGUIDELINES FOR INTERACTIONS OF CLINICIANS AND RESEARCHERS WITH INDUSTRY
GUIDELINES FOR INTERACTIONS OF CLINICIANS AND RESEARCHERS WITH INDUSTRY Overview The overriding goal of these guidelines is to ensure to the fullest extent possible that the integrity of clinical and research
More informationPhysician Payments Disclosure and Aggregate Spend:
Physician Payments Disclosure and Aggregate Spend: Navigating Conflicting and Unclear State Laws and Regulations A Guide for Device Manufacturers October 26, 2010 Colin J. Zick Foley Hoag LLP czick@foleyhoag.com
More informationThe Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector
The Mexico City Principles For Voluntary Codes of Business Ethics in the Biopharmaceutical Sector E thical interactions help ensure that medical decisions are made in the best interests of patients. For
More informationThe Orthopaedic Surgeon s Relationship with Industry
Opinion on Ethics and Professionalism The Orthopaedic Surgeon s Relationship with Industry An AAOS Opinion on Ethics and Professionalism is an official AAOS statement dealing with an ethical issue, which
More informationComparison of the AdvaMed Code of Ethics and the Eucomed Code of Business Practice
Comparison of the AdvaMed Code of Ethics and the Eucomed Code of Business Practice Note: The Eucomed Code also contains Guidelines on Competition Law. These principles discuss trade association rules and
More informationFOR REFERENCE ONLY. Document Change Record: COR NUMBER INITIATOR DESCRIPTION OF CHANGE DATE OF CHANGE REV #
Title: Relationships with Health Care Professionals Document Change Record: REV # DATE OF CHANGE COR NUMBER INITIATOR OF CHANGE DESCRIPTION OF CHANGE 0 9/18/09 16795 Cheryl Garvin Initial Release Quality
More informationCodes of Ethics. (Version 1) June 2013
(Version 1) June 2013 Content: Page 1 Purpose. 1 2 General Principles 1 3 Definitions. 2 4 Consulting Arrangements with Healthcare Professionals 2 5 Third Party Educational Conferences 3 6 Company-Sponsored
More informationAPACMED CODE OF ETHICAL CONDUCT FOR INTERACTIONS WITH HEALTH CARE PROFESSIONALS
APACMED CODE OF ETHICAL CONDUCT FOR INTERACTIONS WITH HEALTH CARE PROFESSIONALS APACMED MISSION: Our mission is to improve the standards of care through innovative collaborations among stakeholders to
More informationFlorida International University Herbert Wertheim College of Medicine Industry Relations Policy and Guidelines 2/16/15
Table of Contents Florida International University Herbert Wertheim College of Medicine Industry Relations Policy and Guidelines 2/16/15 1. INTRODUCTION AND SCOPE OF POLICY 1 2. DEFINITIONS 1 3. STATEMENT
More informationINDUSTRY RELATIONSHIPS
INDUSTRY RELATIONSHIPS STANDARDS OF PROFESSIONALISM Orthopaedic Surgeon-Industry Relationships Adopted April 18, 2007; Proposed revisions will be voted on by the Fellowship after the 2012 Annual Meeting.
More informationADVOCATE HEALTH CARE GUIDELINES FOR VENDOR RELATIONS
ADVOCATE HEALTH CARE GUIDELINES FOR VENDOR RELATIONS PURPOSE: To provide guidelines for ethical conduct to all Advocate Health Care associates and physicians, as well as individuals and organizations who
More informationCAUTION. Introduction
Introduction Most physicians strive to work ethically, render high-quality medical care to their patients, and submit proper claims for payment. Society places enormous trust in physicians, and rightly
More informationWEST PENN ALLEGHENY HEALTH SYSTEM
WEST PENN ALLEGHENY HEALTH SYSTEM Policy Name: Vendor Conduct Policy Page 1 of 8 Original Date: June 9, 2009 Reviewed by: Kathy DeLacio Date of Review: Date of Revision: May 21, 2013 Revision: 2 Document
More informationAsia Pacific Medical Technology Association CODE OF ETHICAL CONDUCT. For Interactions With Health Care Professionals
Asia Pacific Medical Technology Association CODE OF ETHICAL CONDUCT APACMed MISSION: Our mission is to improve the standards of care through innovative collaborations among stakeholders to jointly shape
More informationThe following ACCME Standards are particularly relevant to commercial support:
MUSC Office of CME (OCME) Policies on External Funding of CME Activities MUSC Office of Continuing Medical Education Policies on External Funding of CME Activities MUSC Office of Continuing Medical Education
More informationProfessional Practices Policy (P3)
Novartis Global Policy Professional Practices Policy (P3) Novartis Global Policy March 1st, 2018 Version GIC 102.V1.EN NOVARTIS GLOBAL POLICY 2 Contents 1 Introduction... 3 2 Principles... 4 3 Policy...
More information> TITLE 13. LAW AND PUBLIC SAFETY
N.J.A.C. 13:45J-1.1 13:45J-1.1 Purpose The rules in this chapter regulate the receipt and acceptance by prescribers of anything of value from pharmaceutical manufacturers to ensure that such relationships
More informationContent. Preamble 3. PART A Interaction with Health Care Professionals 5. I. Member-sponsored product training & education 5
CODE OF ETHICS Content Preamble 3 PART A Interaction with Health Care Professionals 5 I. Member-sponsored product training & education 5 II. Supporting third party educational conferences 6 III. Sales
More informationPhysician/Industry Contacts: Updated Focus on CME & Grassley Looks at Possible Research Conflicts
Physician/Industry Contacts: Updated Focus on CME & Grassley Looks at Possible Research Conflicts AdvaMed Webinar // October 28, 2008 R. Michael Scarano, Jr. Heidi A. Sorensen Judith A. Waltz 10/20/2008
More informationLivaNova Terms and Conditions for Donations and Grants
LivaNova Terms and Conditions for Donations and Grants The following Terms and Conditions apply to all LivaNova Donations and Grants approved by the LivaNova regional Donation and Grant Committees, including;
More informationGRANT AND CHARITABLE DONATIONS POLICY
GRANT AND CHARITABLE DONATIONS POLICY I. Purpose and Scope Wright Medical Technology s ( the Company ) commitment to foster charitable donations and giving, and to encourage research and education, is
More informationCOMPARISON CHART: ADVAMED CODE (2005), REVISED ADVAMED CODE (EFF. 7/1/2009) AND REVISED PHRMA CODE (EFF. 1/1/2009)
COMPARISON CHART: ADVAMED CODE (2005), REVISED ADVAMED CODE (EFF. 7/1/2009) AND REVISED PHRMA CODE (EFF. 1/1/2009) Subject 1 AdvaMed Code (2005) Revised AdvaMed Code (eff. 7/1/2009) 2 Revised PhRMA Code
More informationCBI s 7 th Annual Medical Device and Diagnostics Compliance Congress
CBI s 7 th Annual Medical Device and Diagnostics Compliance Congress Compliance Risk Areas related to Educational Programs and Product Training June 7-8, 2011 Laura Keidan Martin National Chair, Health
More informationOMeGA Medical Grants Association RESIDENCY/CORE COMPETENCY INNOVATION GRANT RECIPIENT AGREEMENT. Order number* Program applicant name*
OMeGA Medical Grants Association 2015-2016 RESIDENCY/CORE COMPETENCY INNOVATION GRANT RECIPIENT AGREEMENT Order number* Program applicant name* This Grant Recipient Agreement is between OMeGA Medical Grants
More informationACCME at the International Pharmaceutical Compliance Summit. Philadelphia March 2005
ACCME at the International Pharmaceutical Compliance Summit Philadelphia March 2005 Murray Kopelow, MD, MSC, FRCPC No financial relationships with any commercial interests ACCME s Mission the identification,
More informationALLEGHENY GENERAL HOSPITAL Pittsburgh, Pennsylvania
ALLEGHENY GENERAL HOSPITAL Pittsburgh, Pennsylvania Policy Manual No. 1266 Page 1 SUBJECT: DISCLOSURES OF PROPRIETARY OR FINANCIAL CONFLICTS IN CONTINUING MEDICAL EDUCATION (CME), GRADUATE MEDICAL EDUCATION
More informationUMass Memorial Medical Center Policy 1143 Vendor Relationships
Page 1 of 10 (Vendor Relationships) UMass Memorial Medical Center Policy 1143 Vendor Relationships Developed By: Compliance Office Effective Date: 12/3/2012 Approved by: Jennifer Daley, MD Chief Operating
More informationSTANDARDS OF CONDUCT A MESSAGE FROM THE CHANCELLOR INTRODUCTION COMPLIANCE WITH THE LAW RESEARCH AND SCIENTIFIC INTEGRITY CONFLICTS OF INTEREST
STANDARDS OF CONDUCT A MESSAGE FROM THE CHANCELLOR Dear Faculty and Staff: At Vanderbilt University, patients, students, parents and society at-large have placed their faith and trust in the faculty and
More informationSponsorship of Health Workers and Institutions for Professional Development and Scientific Research
Guideline Recommended February 2017 Sponsorship of Health Workers and Institutions for Professional Development and Scientific Research Guideline Recommended February 2017 Issuing department Nestlé Nutrition
More informationSECTION PROPOSAL FOR EDUCATION ACTIVITY:
SECTION PROPOSAL FOR EDUCATION ACTIVITY: PROPOSAL A.S.P.E.N. Sections: To obtain approval for Section Meetings at Clinical Nutrition Week that have an education program planned (guest speakers and presentations),
More informationARNOLD & PORTER UPDATE
ARNOLD & PORTER UPDATE Guide for Pharmaceutical Industry October 2002 On Monday, September 30, 2002, the Office of Inspector General, U.S. Department of Health and Human Services ( HHS OIG or OIG ) released
More informationThe American Occupational Therapy Association Advisory Opinion for the Ethics Commission. Ethical Considerations in Private Practice
The American Occupational Therapy Association Advisory Opinion for the Ethics Commission Ethical Considerations in Private Practice For occupational therapy practitioners with an entrepreneurial spirit
More informationAANS/NREF/NPA Guidelines for Corporate Relations
AANS/NREF/NPA Guidelines for Corporate Relations What is the intent of the guidelines? The American Association of Neurological Surgeons (AANS) is dedicated to advancing the specialty of neurological surgery
More informationYour role in the CME Activity: Presenter Author Planning Committee Moderator Program Director. Title of CME Activity: Activity Date:
Allegheny General Hospital Department of Continuing Medical Education DISCLOSURE OF RELATIONSHIPS AND DECLARATION FORM Must be completed by all persons involved in CME activities. Failure to disclose prohibits
More informationSPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY
SPONSORSHIP AND JOINT WORKING WITH THE PHARMACEUTICAL INDUSTRY 1 SUMMARY This document sets out Haringey Clinical Commissioning Group policy and advice to employees on sponsorship and joint working with
More informationTHE SUNSHINE ACT I T S I M P L I C AT I O N S F O R C O N T I N U I N G M E D I C A L E D U C AT I O N
THE SUNSHINE ACT I T S I M P L I C AT I O N S F O R C O N T I N U I N G M E D I C A L E D U C AT I O N BACKGROUND Addresses physician sunshine provisions of The Affordable Care Act (a.k.a. ObamaCare ).
More informationGuidelines for Pharmacists Relationship with the Pharmaceutical Industry
Guidelines for Pharmacists Relationship with the Pharmaceutical Industry July 2002 These guidelines represent general advice to support and assist pharmacists. It is expected that professional judgement
More informationCode of Conduct. at Stamford Hospital
Code of Conduct at Stamford Hospital As a Planetree hospital, we are committed to personalizing, humanizing and demystifying the healthcare experience for patients and their families. Our approach is holistic
More informationAPACMED CODE OF ETHICAL CONDUCT FOR INTERACTIONS WITH HEALTH CARE PROFESSIONALS Q&A
APACMED CODE OF ETHICAL CONDUCT FOR INTERACTIONS WITH HEALTH CARE PROFESSIONALS Q&A APACMed Founded in 2014, the Asia Pacific Medical Technology Association (APACMed) is the first and only regional association
More informationInternational Federation of Pharmaceutical Manufacturers & Associations. IFPMA Code of Practice
International Federation of Pharmaceutical Manufacturers & Associations IFPMA Code of Practice 2012 Foreword Advancing medical knowledge and improving global public health depend on information-sharing
More informationPOLICY: Conflict of Interest
POLICY: Conflict of Interest A. Purpose Conducting high quality research and instructional activities is integral to the primary mission of California University of Pennsylvania. Active participation by
More informationVersion 1.0. Quality, Performance & Finance. Date Ratified 31 st March 2015 Iain Stewart, Head of Direct Commissioning
Joint working with the pharmaceutical industry Policy (Template based upon DH Best Practice Guidance for Joint Working between the NHS and the Pharmaceutical Industry, February 2008) Version 1.0 Ratified
More informationNew Jersey issues rules to chill drug manufacturer payments to prescribers
New Jersey issues rules to chill drug manufacturer payments to prescribers January 10, 2018 The New Jersey Attorney General plans to finalize new limits on payments and other benefits that New Jersey licensed
More informationGuiding Principle... 2
Effective Date: September 22, 2008 Updated: May 2012, September 2014, November 2015, June 2016, May 19, 2017 Contents Guiding Principle... 2 Commercial Support... 2 How is commercial support defined?...
More informationCompliance Program And Code of Conduct. United Regional Health Care System
Compliance Program And Code of Conduct United Regional Health Care System TABLE OF CONTENTS Page MESSAGE FROM OUR PRESIDENT... 1 COMPLIANCE PROGRAM... 2 Program Structure...2 Management s Responsibilities
More informationUCLA HEALTH SYSTEM CODE OF CONDUCT
UCLA HEALTH SYSTEM CODE OF CONDUCT STANDARD 1 - QUALITY OF CARE The University s health centers and health systems will provide quality health care that is appropriate, medically necessary, and efficient.
More informationReprinted from FDA s website by
Reprinted from FDA s website by POLICY AND PROCEDURES PURPOSE OFFICE OF EXECUTIVE PROGRAMS Accreditation -- Continuing Education Table of Contents PURPOSE...1 BACKGROUND...1 POLICY...3 RESPONSIBILITIES...7
More informationCME Policies & Procedures
CME Policies & Procedures Updated January 2017 Grand Rapids Medical Education Partners is accredited by the Michigan State Medical Society to provide Continuing Medical Education (CME) for physicians.
More informationAshland Hospital Corporation d/b/a King s Daughters Medical Center Corporate Compliance Handbook
( Medical Center ) conducts itself in accord with the highest levels of business ethics and in compliance with applicable laws. This goal can be achieved and maintained only through the integrity and high
More informationAmerican Head & Neck Society
American Head & Neck Society CODE FOR INTERACTIONS WITH COMPANIES 11300 W. Olympic Blvd, Suite 600, Los Angeles, CA 90064 310-437-0559 310-437-0585 The single largest organization in North America for
More informationAmerican Osteopathic College Disclosure to Learners For Continuing Medical Education Activities
American Osteopathic College Disclosure to Learners For Continuing Medical Education Activities The Continuing Medical Education Program of the American Osteopathic College of Dermatology will support
More informationSTANDARDS AND REQUIREMENTS FOR APPROVAL OF PROVIDERS OF CONTINUING EDUCATION IN PODIATRIC MEDICINE. Council on Podiatric Medical Education
STANDARDS AND REQUIREMENTS FOR APPROVAL OF PROVIDERS OF CONTINUING EDUCATION IN PODIATRIC MEDICINE Council on Podiatric Medical Education TABLE OF CONTENTS INTRODUCTION... 2 ABOUT THIS DOCUMENT... 3 INFORMATION
More informationCONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION
CONSENSUS FRAMEWORK FOR ETHICAL COLLABORATION November 2016 ABOUT CORD The Canadian Organization for Rare Disorders (CORD) provides a strong common voice to advocate for health policy and a healthcare
More informationContinuing Medical Education (CME) Endorsement Application Guide
Continuing Medical Education (CME) Endorsement pplication Guide Contents bout the College 1 What is CME? 1 Who must do CME? 1 Use of the RNZCGP endorsed event logo 4 Using the online system 4 uestions
More informationAMERICAN ASSOCIATION FOR HOMECARE CODE OF BUSINESS ETHICS FREQUENTLY ASKED QUESTIONS. 1) Why did AAHomecare revise its Code of Business Ethics?
AMERICAN ASSOCIATION FOR HOMECARE CODE OF BUSINESS ETHICS FREQUENTLY ASKED QUESTIONS A. Preamble: Goal and Scope 1) Why did AAHomecare revise its Code of Business Ethics? AAHomecare and Members are committed
More informationPhysician Referral: Laws, Rules, and Ethics
Physician Referral: Laws, Rules, and Ethics Nabil El Sanadi, MD, MBA, FACEP Chairman, Council on Ethical and Judicial Affairs, Florida Medical Association Chief of Emergency Medicine, Broward Health Clinical
More informationSTANDARDS OF CONDUCT SCH
STANDARDS OF CONDUCT SCH01242018 2018 LETTER FROM THE CEO Welcome, Thank you for choosing St. Croix Hospice. The care you provide impacts our patients, families, caregivers, and countless others every
More informationEducational Grant Application
Educational Grant Application Please complete all application contents below. This information is REQUIRED to process your application. Requests must be submitted to EdGrants@nevro.com a minimum of 21
More informationPolicy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry
Policy for the Sponsorship of Activities and Joint Working with the Pharmaceutical Industry March 2017 NOTE: This policy will be subject to review in 2017/18 as part of the partnership work between North
More informationApril, 2007 QUESTIONABLE PRACTICES BY HOSPICES AND NURSING HOMES UNDER HEALTH CARE FRAUD AND ABUSE RULES
HOSPICE AND PALLIATIVE CARE PRACTICE GROUP: Mary H. Michal, Chair Linda Dawson Meg S.L. Pekarske Matthew K. McManus LONG TERM CARE AND SENIOR HOUSING PRACTICE GROUP: Robert J. Heath, Chair Burton A. Wagner
More informationCompliance Program, Code of Conduct, and HIPAA
Compliance Program, Code of Conduct, and HIPAA Agenda Introduction to Compliance The Compliance Program Code of Conduct Reporting Concerns HIPAA Why have a Compliance Program Procedures to follow applicable
More informationFAQ FREQUENTLY ASKED QUESTIONS BUSINESS COURTESIES, GIFTS & SUPPLIER RELATIONS. A supplement to Code of Conduct
FAQ FREQUENTLY ASKED QUESTIONS BUSINESS COURTESIES, GIFTS & SUPPLIER RELATIONS A supplement to Code of Conduct Table of CONTENTS 3 6 6 7 8 9 10 11 12 Business Courtesies, Gifts and Supplier Relations Doing
More informationBUSINESS RELATIONSHIPS BETWEEN STAFF AND PHARMACEUTICAL INDUSTRY REPRESENTATIVES
Department of Veterans Affairs MEMORANDUM NO. 119-11 North Florida/South Georgia Veterans Health System Change 2 June 1, 2005 BUSINESS RELATIONSHIPS BETWEEN STAFF AND PHARMACEUTICAL INDUSTRY REPRESENTATIVES
More informationCODE OF ETHICS ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS IN CHINA
CODE OF ETHICS ON INTERACTIONS WITH HEALTH CARE PROFESSIONALS IN CHINA ADOPTED BY THE CHINA BOARD OF THE ADVANCED MEDICAL TECHNOLOGY ASSOCIATION Revised Effective January 1, 2017 I. Preamble: Goal and
More informationIntroduction...2. Purpose...2. Development of the Code of Ethics...2. Core Values...2. Professional Conduct and the Code of Ethics...
CODE OF ETHICS Table of Contents Introduction...2 Purpose...2 Development of the Code of Ethics...2 Core Values...2 Professional Conduct and the Code of Ethics...3 Regulation and the Code of Ethic...3
More informationMedicare Advantage and Part D Fraud, Waste and Abuse Compliance Training 2015
Medicare Advantage and Part D Fraud, Waste and Abuse Compliance Training 2015 Overview This Medicare Advantage and Part D Fraud, Waste and Abuse Compliance Training for first-tier, downstream and related
More informationISDN. Over the past few years, the Office of the Inspector General. Assisting Network Members Develop and Implement Corporate Compliance Programs
Information Bulletin #7 ISDN National Association of Community Health Centers, Inc. INTEGRATED SERVICES DELIVERY NETWORKS SERIES For more information contact Jacqueline C. Leifer, Esq. or Marcie H. Zakheim,
More informationExecutive Summary, November 2015
Medicare Physician Fee Schedule Final Rule for Calendar Year 2016 Makes Changes in Stark Law Regulatory Provisions and Contains Important Updates of Medicare Payment Policies Executive Summary, November
More informationSt. Jude Children s Research Hospital. Code of Conduct
1 St. Jude Children s Research Hospital Code of Conduct 2 Dear Colleague: As a global leader in the research and treatment of pediatric catastrophic diseases, St. Jude Children s Research Hospital has
More informationCompliance Program Code of Conduct
City and County of San Francisco Department of Public Health Compliance Program Code of Conduct Purpose of our Code of Conduct The Department of Public Health of the City and County of San Francisco is
More informationBIPI Medical Education Grants Sunshine Reporting Requirements
BIPI Medical Education Grants Sunshine Reporting Requirements The following information is intended to assist applicants in understanding the conditions and requirements surrounding applicants reporting
More informationContinuing Education: Perspective from a Commercial Supporter
Continuing Education: Perspective from a Commercial Supporter Cathryn M. Clary, MD Vice President, US External Medical Affairs Pfizer Inc December 11, 2008 1 Disclosures: Cathryn Clary, MD n Full time
More informationArabio Code of Promotional and Marketing Practices 2016
Code of Promotional and Marketing Practices August 2016 V.1. Table of Contents Page 2. A message from the Board of Directors 3. Saudi FDA Guiding Principles 4. Preamble 5. (ARTICLE 1) Scope and Definitions
More informationTHE MONTEFIORE ACO CODE OF CONDUCT
THE MONTEFIORE ACO CODE OF CONDUCT 2017 Approved by the Board of Directors on March 10, 2017 Our Commitment to Compliance As a central part of its Compliance Program, the Bronx Accountable Healthcare Network
More informationCODE OF CONDUCT Q&A. Medicines for Europe. Follow us on
CODE OF CONDUCT Q&A Medicines for Europe Follow us on Rue d Arlon 50-1000 Brussels Belgium T: +32 (0)2 736 84 11- F: +32 (0)2 736 74 38 www.medicinesforeurope.com 1 Code of Conduct Q&A Contents Introductory
More informationCCG Policy for Working with the Pharmaceutical Industry
CCG Policy for Working with the Pharmaceutical Industry 1. Introduction Medicines are the most frequently and widely used NHS treatment and account for over 12% of NHS expenditure. The Pharmaceutical Industry
More informationValidation of Education Activity Content. All departments developing and presenting continuing education programs certified for credit by LVHN.
Page: 1 of 5 I. PURPOSE To establish criteria, policy and process for the validation of the clinical content of Continuing Education activities in accordance with Accreditation Council for Continuing Medical
More informationPOLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH
POLICY FOR SPONSORSHIP OF ACTIVITIES, JOINT WORKING AND TRAINING AND EDUCATION BY THE PHARMACEUTICAL INDUSTRY WITH NOTTINGHAMSHIRE CLINICAL COMMISSIONING GROUPS Contents 1. Background... 3 2. Purpose of
More informationContinuing Education Guidelines. 5 Hanover Square, Suite 1401 New York, NY tel: (917) fax: (212)
Continuing Education Guidelines 5 Hanover Square, Suite 1401 New York, NY 10004 tel: (917) 746-8300 fax: (212) 785-1713 Email: lnelsen@napnap.org NAPNAP Continuing Education Guidelines I. Overview Page
More informationThe Act, which amends the Small Business Act ([15 USC 654} 15 U.S.C. 654 et seq.), is intended to:
Drug-Free Workplace Act of 1998 PM:249:7651 In This Chapter SUMMARY OF PROVISIONS OVERVIEW The Drug-Free Workplace Act of 1998 was enacted as part of the Omnibus Consolidated and Emergency Supplemental
More informationAssociate(s): Includes practicing health care professionals and employees working at Ascension Health facilities.
Ascension Health Vendor Access Policy Purpose: The purpose of this policy is to set forth guidelines for relationships with Health Care Industry Representatives (HCIR). Ascension Health desires to provide
More informationFoundations Health Solutions Nursing Facility Integrity Manual Revised August 2017
Foundations Health Solutions Nursing Facility Integrity Manual Revised August 2017 T A B L E O F C O N T E N T S Our Commitment to Integrity... 3 1.0 Code of Ethics... 5 2.0 Reporting & Response (Disclosure
More informationHANDBOOK FOR THE INDIGENOUS ECONOMIC DEVELOPMENT FUND. January 2018
HANDBOOK FOR THE INDIGENOUS ECONOMIC DEVELOPMENT FUND January 2018 (WHAT YOU NEED TO KNOW BEFORE YOU APPLY) Before completing an Indigenous Economic Development Fund (IEDF) application, please read the
More informationRUTGERS BIOMEDICAL AND HEALTH SCIENCES CODE OF CON DU CT
RUTGERS BIOMEDICAL AND HEALTH SCIENCES CODE OF CONDUCT PREAMBLE On August 22, 2012, Governor Chris Christie signed legislation into law known as the New Jersey Medical and Health Sciences Education Restructuring
More informationCode of Ethical Conduct for Interactions with Healthcare Professionals. Singapore Manufacturing Federation Medical Technology Industry Group
Code of Ethical Conduct for Interactions with Healthcare Professionals Singapore Manufacturing Federation Medical Technology Industry Group Table of Contents About SMF Medical Technology Industry Group
More informationBUSINESS RELATIONSHIPS BETWEEN STAFF AND PHARMACEUTICAL COMPANY REPRESENTATIVES
Department of Veterans Affairs MEMORANDUM NO. 119-11 North Florida/South Georgia Veterans Health System Change 5 March 15, 2013 BUSINESS RELATIONSHIPS BETWEEN STAFF AND PHARMACEUTICAL COMPANY REPRESENTATIVES
More informationCME COALITION M A Y 2 1,
1 CME COALITION THOUGHTS ON IMPLEMENTATION OF THE PHYSICIAN PAYMENT SUNSHINE ACT PRESENTED TO CMS M A Y 2 1, 2 0 1 3 Introductions Tina B. Stacy, PharmD, BCOP, CCMEP, President, Educational Concepts Group,
More informationSponsorship guidance for all accredited activities
QI&CPD Program Sponsorship guidance for all accredited activities 2017 19 www.racgp.org.au 2017 19 triennium Sponsorship guidance for all accredited activities: QI&CPD Program 2017 19 triennium Disclaimer
More informationBUILDING YOUR TOOLBOX TO MANAGE CONFLICT OF INTEREST: SUNSHINE, OPEN PAYMENTS, AND INVESTIGATIONS
BUILDING YOUR TOOLBOX TO MANAGE CONFLICT OF INTEREST: SUNSHINE, OPEN PAYMENTS, AND INVESTIGATIONS 2017 HCCA Compliance Institute, National Harbor, MD Presented by CJ Wolf, MD, CHC, CCEP, CIA, COC, CPC
More informationFSA Code of Conduct on the Collaboration with Patient Organisations. ("FSA Code of Conduct Patient Organisations")
FSA Code of Conduct on the Collaboration with Patient Organisations ("FSA Code of Conduct Patient Organisations") Dated 13 June 2008 (announced in the Federal Gazette of 23 July 2008, BAnz. No. 109, S.
More informationCompliance Program Updated August 2017
Compliance Program Updated August 2017 Table of Contents Section I. Purpose of the Compliance Program... 3 Section II. Elements of an Effective Compliance Program... 4 A. Written Policies and Procedures...
More informationStatement of Guidance: Outsourcing Regulated Entities
Statement of Guidance: Outsourcing Regulated Entities 1. STATEMENT OF OBJECTIVES 1.1 This Statement of Guidance ( Guidance ) is intended to provide guidance to regulated entities on the establishment of
More informationDEPARTMENT OF CONTINUING MEDICAL EDUCATION POLICIES
DEPARTMENT OF CONTINUING MEDICAL EDUCATION POLICIES Beaumont Health, hereinafter referred to as Beaumont, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) and the American
More informationTypes of Authorized Recipients Probation/Parole Officers or the Department of Corrections
Types of Authorized Recipients Probation/Parole Officers or the Department of Corrections Research current through May 2016. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office
More informationEMPLOYEE HANDBOOK EMPLOYEE HANDBOOK. Code of Conduct
EMPLOYEE HANDBOOK EMPLOYEE HANDBOOK L E A D I N G T E A C H I N G C A R I N G CODE OF CON DUCT Who We Are and What We Stand For In 2016, UNC Health Care adopted a system-wide. The purpose of this is to
More information